Amarin reported $122.8M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.63B 838M Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
Amarin USD 122.8M 25.08M Sep/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
DBV Technologies USD 69.84M 33.37M Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Halozyme Therapeutics USD 419.66M 357.8M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Neurocrine Biosciences USD 340.2M 76.2M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025